الفهرس 
? Polycystic Ovary SyndromeOnly 14 pages are availabe for public view
 |  | from | 111 |  |  |
| | | from | 111 | | |
Abstract
Figure 1: Consort flow chart of this RCT. 58
Figure 2: Proportion of patients with regular or irregular menses at 3 months by per protocol (PP) analysis. 62
Figure 3: Proportion of patients with or without ovulation at 3 months by per protocol (PP) analysis. 62
Figure 4: Proportion of patients with positive or negative pregnancy at 3 months by per protocol (PP) analysis. 63
Figure 5: Proportion of patients with or without ovulation at 5 months by per protocol (PP) analysis. 65
Figure 6: Proportion of patients with positive or negative pregnancy at 5 months by per protocol (PP) analysis. 65
Figure 7: Proportion of patients with regular or irregular menses at 3 months by intention-to-treat (ITT) analysis. 67
Figure 8: Proportion of patients with or without ovulation at 3 months by intention-to-treat (ITT) analysis. 67
Figure 9: Proportion of patients with positive or negative pregnancy at 3 months by intention-to-treat (ITT) analysis. 68
Figure 10: Proportion of patients with or without ovulation at 5 months by intention-to-treat (ITT) analysis. 70
Figure 11: Proportion of patients with positive or negative pregnancy at 5 months by per protocol (PP) analysis. 70
Therapeutic Effect of Vitamin D3 Supplementation to Clomiphene Citrate Resistant PCOS Women: A Randomized Controlled Trial
Prof. Dr. Ahmed Mohamed Nour El-Din Hashaad, Dr. Reda Mokhtar Kamal Ghanem, Sara Abouelfath Abouelasrar Gad Dawoud
Obstetrics & Gynaecology Department, Faculty of Medicine, Ain Shams University
ABSTRACT
Background: Polycystic ovary syndrome (PCOS) is considered one of the most common endocrine disorders affecting females in their reproductive age. While insulin resistance (which affects 50 – 70 % of PCOS patients) is considered to be the main reason for hyperandrogenic features, PCOS also leads to various health problems including metabolic disorders (obesity – DM – CVS diseases) in addition to menstrual irregularities and infertility.
Objectives: To The aim of the work is to assess the efficacy of vitamin D supplementation in improving ovulation induction in PCOS women (1ry outcome) and increasing pregnancy rate (secondary outcome).
Patients and Methods: Randomized controlled trial was conducted at Ain Shams University Maternity Hospital in the period from May 2018 to March 2019. The population of this study was 120 women who attended the infertility clinic (aged 20-35 years, BMI 18-35 kg\m2), diagnosed PCOS according to Rotterdam criteria and were resistant to CC treatment. Women were randomly allocated into equal two groups: group V: number of 60 patients received 100000 IU cholecalciferol 2.5 mg (1ml of Devarol-S- 2ml ampoule 200000 IU- 5mg cholecalciferol-,Memphis, IM.) once per month. + Metformin (Glucophage 1000XR, Merk Sante, Germany, oral: 2 tablets per day) for 2 months. group C: 60 patients received Metformin (Glucophage 1000XR, Merk Sante, Germany, oral: 2 tablets per day) for 2 months.
Results: In our study results, regulation of menstrual cycle occured in 63.6% of women who recieved vitamin D + metformin (group V) and ovulation was confirmed in 34.5% of the total number (55 women). Later, 18% of them got pregnant after 3 months of treatment. Added to that 16 women out of 39 (41%) got pregnant by the end of the follow up period with cumulative pregnancy rate (53%). On the other hand menstrual regularity in (group C: metformin) recorded 61% with ovulation percentage of 26.9% (n=54). Followed by 14.8% pregnancy rate at the 3rd month.
Conclusion: from the current study we can conclude that there is no significant difference of adding vitamin D to CC resistant PCOS regarding ovulation and pregnancy rates. However, it can augment metformin action and improves its outcome.